References
- Berger L, Luc G, Richard D. L’esthesioneuroepitheliome olfactif. Bull Assoc Fr Etud Cancer. 1924;13:410–421.
- Saade RE, Hanna EY, Bell D. Prognosis and biology in esthesioneuroblastoma: the emerging role of Hyams grading system. Curr Oncol Rep. 2015;17(1):423. doi:https://doi.org/10.1007/s11912-014-0423-z.
- Theilgaard SA, Buchwald C, Ingeholm P, Kornum Larsen S, Eriksen JG, Sand Hansen H. Esthesioneuroblastoma: a Danish demographic study of 40 patients registered between 1978 and 2000. Acta Otolaryngol. 2003;123(3):433–439. doi:https://doi.org/10.1080/00016480310001295.
- Diaz EM Jr, Johnigan RH 3rd, Pero C, El-Naggar AK, Roberts DB, Barker JL, et al. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck. 2005;27(2):138–149. doi:https://doi.org/10.1002/hed.20127.
- Fiani B, Quadri SA, Cathel A, Farooqui M, Ramachandran A, Siddiqi I, et al. Esthesioneuroblastoma: a comprehensive review of diagnosis, management, and current treatment options. World Neurosurg. 2019;126:194–211. doi:https://doi.org/10.1016/j.wneu.2019.03.014.
- Rosenthal DI, Barker JL Jr, El-Naggar AK, Glisson BS, Kies MS, Diaz EM Jr, et al. Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype. Cancer. 2004;101(11):2567–2573. doi:https://doi.org/10.1002/cncr.20693.
- Charles NC, Petris CK, Kim ET. Aggressive esthesioneuroblastoma with divergent differentiation: A taxonomic dilemma. Orbit. 2016;35(6):357–359. doi:https://doi.org/10.1080/01676830.2016.1193537.
- Rimmer J, Lund VJ, Beale T, Wei WI, Howard D. Olfactory neuroblastoma: a 35-year experience and suggested follow-up protocol. Laryngoscope. 2014;124(7):1542–1549. doi:https://doi.org/10.1002/lary.24562.
- Thompson LD. Small round blue cell tumors of the sinonasal tract: a differential diagnosis approach. Mod Pathol. 2017;30(s1):S1–S26. doi:https://doi.org/10.1038/modpathol.2016.119.
- Bachar G, Goldstein DP, Shah M, Tandon A, Ringash J, Pond G, et al. Esthesioneuroblastoma: the princess margaret hospital experience. Head Neck. 2008;30(12):1607–1614. doi:https://doi.org/10.1002/hed.20920.
- Dulguerov P, Allal AS, Calcaterra TC. Esthesioneuroblastoma: a meta-analysis and review. Lancet Oncol. 2001;2(11):683–690. doi:https://doi.org/10.1016/S1470-2045(01)00558-7.
- Lund VJ, Howard D, Wei W, Spittle M. Olfactory neuroblastoma: past, present, and future? Laryngoscope. 2003;113(3):502–507. doi:https://doi.org/10.1097/00005537-200303000-00020.
- Fitzek MM, Thornton AF, Varvares M, Ancukiewicz M, Mcintyre J, Adams J, et al. Neuroendocrine tumors of the sinonasal tract. Results of a prospective study incorporating chemotherapy, surgery, and combined proton-photon radiotherapy. Cancer. 2002;94(10):2623–2634. doi:https://doi.org/10.1002/cncr.10537.
- Polin RS, Sheehan JP, Chenelle AG, Munoz E, Larner J, Phillips CD, et al. The role of preoperative adjuvant treatment in the management of esthesioneuroblastoma: the University of Virginia experience. Neurosurgery. 1998;42(5):1029–1037. doi:https://doi.org/10.1097/00006123-199805000-00045.
- Loy AH, Reibel JF, Read PW, Thomas CY, Newman SA, Jane JA, et al. Esthesioneuroblastoma: continued follow-up of a single institution’s experience. Arch Otolaryngol Head Neck Surg. 2006;132(2):134–138. doi:https://doi.org/10.1001/archotol.132.2.134.
- Bobele GB, Sexauer C, Barnes PA, Krous HF, Bodensteiner JB. Esthesioneuroblastoma presenting as an orbital mass in a young child. Med Pediatr Oncol. 1994;22(4):269–273. doi:https://doi.org/10.1002/mpo.2950220411.
- Kurian S, Ertan E, Ducatman B, Crowell EB, Rassekh C. Esthesioneuroblastoma in Maffucci’s syndrome. Skeletal Radiol. 2004;33(10):609‐612. doi:https://doi.org/10.1007/s00256-004-0802-x.
- Laforest C, Selva D, Crompton J, Leibovitch I. Orbital invasion by esthesioneuroblastoma. Ophthalmic Plast Reconstr Surg. 2005;21(6):435‐440. doi:https://doi.org/10.1097/01.iop.0000184322.79438.2b.
- Díez-Villalba R, González-Ruiz M, Izquierdo-Vázquez C, Molina-Quirós C, Colmenero-Ruiz M, Ramos-Amador A, et al. Debut oftalmológico de dos casos de estesioneuroblastoma [Ophthalmic presentation of two cases of esthesioneuroblastoma]. Arch Soc Esp Oftalmol. 2008;83(5):317–320. doi:https://doi.org/10.4321/S0365-66912008000500007.
- García-Santana SM, Rodríguez JA, Serrano L, Hedges TR 3rd. Esthesioneuroblastoma presenting with complete external ophthalmoplegia. Semin Ophthalmol. 2009;24(6):245‐246. doi:https://doi.org/10.3109/08820530903388587.
- Yu T, Xu YK, Li L, Jia FG, Duan G, Wu YK, et al. Esthesioneuroblastoma methods of intracranial extension: CT and MR imaging findings. Neuroradiology. 2009;51(12):841–850. doi:https://doi.org/10.1007/s00234-009-0581-0.
- Turano S, Mastroianni C, Manfredi C, Biamonte R, Ceniti S, Liguori V, et al. Advanced adult esthesioneuroblastoma successfully treated with cisplatin and etoposide alternated with doxorubicin, ifosfamide and vincristine. J Neurooncol. 2010;98(1):131–135. doi:https://doi.org/10.1007/s11060-009-0052-9.
- Aggarwal SK, Kumar R, Shrivastav A, Keshri A, Sharma P. Esthesioneuroblastoma presenting with proptosis and bilateral neck metastasis: an unusual presentation. J Pediatr Neurosci. 2011;6:78–81.
- Gupta S, Husain N, Sundar S. Esthesioneuroblastoma chemotherapy and radiotherapy for extensive disease: a case report. World J Surg Oncol. 2011;9:118. doi:https://doi.org/10.1186/1477-7819-9-118.
- Aljumaily RM, Nystrom JS, Wein RO. Neoadjuvant chemotherapy in the setting of locally advanced olfactory neuroblastoma with intracranial extension. Rare Tumors. 2011;3(1):e1. doi:https://doi.org/10.4081/rt.2011.e1.
- Kamath VB, Sowmya V, Ballal CK, Mendonca N. Esthesioneuroblastoma as an unusual cause for dystopia. Orbit. 2013;32(6):392–394. doi:https://doi.org/10.3109/01676830.2013.833252.
- Lopez R, Mazzoni L, Chaput B, Jalbert F. Olfactory neuroblastoma presenting with exclusive orbital manifestations. J Craniofac Surg. 2013;24:667–669.
- Herr MW, Gray ST, Erman AB, Curry WT, Deschler DG, Lin DT. Orbital preservation in patients with esthesioneuroblastoma. J Neurol Surg B Skull Base. 2013;74(3):142–145. doi:https://doi.org/10.1055/s-0033-1338259.
- Ahmed M, Knott PD. Hyperostotic esthesioneuroblastoma: rare variant and fibrous dysplasia mimicker. Korean J Radiol. 2014;15(1):156–160. doi:https://doi.org/10.3348/kjr.2014.15.1.156.
- Niyaz L, Gunduz K, Meco C, Kankaya D. Esthesioneuroblastoma with poor outcome despite extensive treatment. J Craniofac Surg. 2015;26(7):e615–6. doi:https://doi.org/10.1097/SCS.0000000000002114.
- Su SY, Bell D, Ferrarotto R, Phan J, Roberts D, Kupferman ME, et al. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck. 2017;39(8):1671–1679. doi:https://doi.org/10.1002/hed.24822.
- Breazzano MP, Lewis JS Jr, Chambless LB, Rohde SL, Sobel RK. Remote orbital recurrence of olfactory neuroblastoma (esthesioneuroblastoma). Orbit. 2017;36(4):247–250. doi:https://doi.org/10.1080/01676830.2017.1287742.
- Palejwala SK, Sharma S, Le CH, Chang E, Erman AB, Lemole GM Jr. Complex skull base reconstructions in Kadish D esthesioneuroblastoma: case report. J Neurol Surg Rep. 2017;78:e86–e92.
- Bartel R, Gonzalez-Compta X, Cisa E, Cruellas F, Torres A, Rovira A, et al. Importance of neoadjuvant chemotherapy in olfactory neuroblastoma treatment: series report and literature review. Acta Otorrinolaringol Esp. 2018;69(4):208–213. doi:https://doi.org/10.1016/j.otorri.2017.07.001.
- Li R, Tian S, Zhu Y, Yan L, Zhu W, Quan H, et al. Management of orbital invasion in esthesioneuroblastoma: 14 years’ experience. Radiat Oncol. 2019;14(1):107. doi:https://doi.org/10.1186/s13014-019-1313-1.
- Song X, Wang J, Wang S, Yan L, Li Y. Prognostic factors and outcomes of multimodality treatment in olfactory neuroblastoma. Oral Oncol. 2020;103:104618. doi:https://doi.org/10.1016/j.oraloncology.2020.104618.
- Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer. 1976;37(3):1571–1576. doi:https://doi.org/10.1002/1097-0142(197603)37:3<1571::AID-CNCR2820370347>3.0.CO;2-L.
- Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery. 1993;32(5):706–715. doi:https://doi.org/10.1227/00006123-199305000-00002.
- Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope. 1992;102(8):843–849. doi:https://doi.org/10.1288/00005537-199208000-00001.
- Joshi RR, Husain Q, Roman BR, Cracchiolo J, Yu Y, Tsai J, et al. Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. J Surg Oncol. 2019;119(1):130–142. doi:https://doi.org/10.1002/jso.25293.
- Hyams VJ, Batsakis JG, Michaels L. Tumors of the Upper Respiratory Tract and Ear. Washington, DC: Armed Forces Institute of Pathology; 1988:240–248.
- Bell D, Saade R, Roberts D, Ow TJ, Kupferman M, DeMonte F, et al. Prognostic utility of Hyams histological grading and Kadish-Morita staging systems for esthesioneuroblastoma outcomes. Head Neck Pathol. 2015;9(1):51–59. doi:https://doi.org/10.1007/s12105-014-0547-3.
- Zafereo ME, Fakhri S, Prayson R, Batra PS, Lee J, Lanza DC, et al. Esthesioneuroblastoma: 25-year experience at a single institution. Otolaryngol Head Neck Surg. 2008;138(4):452–458. doi:https://doi.org/10.1016/j.otohns.2007.12.038.
- Malouf GG, Casiraghi O, Deutsch E, Guigay J, Temam S, Bourhis J. Low- and high-grade esthesioneuroblastomas display a distinct natural history and outcome. Eur J Cancer. 2013;49(6):1324–1334. doi:https://doi.org/10.1016/j.ejca.2012.12.008.
- Jethanamest D, Morris LG, Sikora AG, Kutler DI. Esthesioneuroblastoma: a population-based analysis of survival and prognostic factors. Arch Otolaryngol Head Neck Surg. 2007;133(3):276–280. doi:https://doi.org/10.1001/archotol.133.3.276.
- Van Gompel JJ, Giannini C, Olsen KD, Moore E, Piccirilli M, Foote RL, et al. Long-term outcome of esthesioneuroblastoma: hyams grade predicts patient survival. J Neurol Surg B Skull Base. 2012;73(5):331–336. doi:https://doi.org/10.1055/s-0032-1321512.
- Kaur G, Kane AJ, Sughrue ME, Madden M, Oh MC, Sun MZ, et al. The prognostic implications of Hyam’s subtype for patients with Kadish stage C esthesioneuroblastoma. J Clin Neurosci. 2013;20(2):281–286. doi:https://doi.org/10.1016/j.jocn.2012.05.029.
- Xiong L, Zeng XL, Guo CK, Liu AW, Huang L. Optimal treatment and prognostic factors for esthesioneuroblastoma: retrospective analysis of 187 Chinese patients. BMC Cancer. 2017;17(1):254. doi:https://doi.org/10.1186/s12885-017-3247-z.
- Porter AB, Bernold DM, Giannini C, Foote RL, Link MJ, Olsen KD, et al. Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neurooncol. 2008;90(2):201–204. doi:https://doi.org/10.1007/s11060-008-9645-y.
- Bhattacharyya N, Thornton AF, Joseph MP, Goodman ML, Amrein PC. Successful treatment of esthesioneuroblastoma and neuroendocrine carcinoma with combined chemotherapy and proton radiation. Results in 9 cases. Arch Otolaryngol Head Neck Surg. 1997;123(1):34–40. doi:https://doi.org/10.1001/archotol.1997.01900010038005.
- Koka VN, Julieron M, Bourhis J, Janot F, Le Ridant AM, Marandas P, et al. Aesthesioneuroblastoma. J Laryngol Otol. 1998;112(7):628–633. doi:https://doi.org/10.1017/S0022215100141295.
- Rakes SM, Yeatts RP, Campbell RJ. Ophthalmic manifestations of esthesioneuroblastoma. Ophthalmology. 1985;92(12):1749–1753. doi:https://doi.org/10.1016/S0161-6420(85)34102-7.
- Garkavij M, Nickel M, Sjögreen-Gleisner K, Ljungberg M, Ohlsson T, Wingårdh K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. Cancer. 2010;116(4 Suppl):1084–1092. doi:https://doi.org/10.1002/cncr.24796.